New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Neumora Therapeutics, Inc.

Contributing Author

Recent Articles by Neumora Therapeutics, Inc.

11 hours	Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 NMRA GlobeNewswire
Jan-05	Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones NMRA GlobeNewswire
Jan-05	Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation NMRA GlobeNewswire
Nov-06	Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update NMRA GlobeNewswire
Nov-03	Neumora Therapeutics to Participate in Upcoming Conferences in November NMRA GlobeNewswire
Oct-27	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 NMRA GlobeNewswire
Oct-27	Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model NMRA GlobeNewswire
Oct-01	Neumora Therapeutics to Host Virtual R&D Day on October 27 NMRA GlobeNewswire
Sep-02	Neumora Therapeutics to Participate in Upcoming Conferences in September NMRA GlobeNewswire
Aug-06	Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update NMRA GlobeNewswire
Jul-23	Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 NMRA GlobeNewswire
Jul-09	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 NMRA +13.12% GlobeNewswire
May-12	Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update NMRA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.